Health-Related SPACs Booming in Pandemic: Report

Trump's SPAC deal features a host of red flags, including the backing of a Chinese firm with a checkered regulatory history, that have captured the attention of federal authorities.

The SPAC argues that a federal judge should throw out a lawsuit from a shareholder who alleges that the SPAC is operating illegally as an investment company.

A handful of high-profile names dominate the rankings of blank-check company dealmakers, as investors and potential targets have become more selective about the wave of special purpose acquisition companies, Financial News reports.

The SPAC's shareholderrs approved the deal in October 2021. At that time, shares were trading around $9.30. Better Therapeutics closed today at $1.13, down 2.59%.